Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Eiji TakeuchiKensuke KondoYoshio OkanoSeiya IchiharaMichihiro KunishigeNaoki KadotaHisanori MachidaNobuo HatakeyamaKeishi NaruseHirokazu OginoHiroshi NokiharaTsutomu ShinoharaYasuhiko Nishioka

Published in: Thoracic cancer (2023)

OS was significantly longer in ICI-treated NSCLC patients with a pretreatment eosinophil count of 100 ≤ Eo <500 than in the other patients and, thus, has potential as a new predictive biomarker.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
small cell lung cancer
chronic kidney disease
peripheral blood
peritoneal dialysis
risk assessment
tyrosine kinase
brain metastases
epidermal growth factor receptor